Nanomedicine-mediated cancer stem cell therapy
Source abstract
Abstract
Circumstantial evidence suggests that most tumours are heterogeneous and contain a small population of cancer stem cells (CSCs) that exhibit distinctive self-renewal, proliferation and differentiation capabilities, which are believed to play a crucial role in tumour progression, drug resistance, recurrence and metastasis in multiple malignancies. Given that the existence of CSCs is a primary obstacle to cancer therapy, a tremendous amount of effort has been put into the development of anti-CSC strategies, and several potential approaches to kill therapeutically-resistant CSCs have been explored, including inhibiting ATP-binding cassette transporters, blocking essential signalling pathways involved in self-renewal and survival of CSCs, targeting CSCs surface markers and destroying the tumour microenvironment. Meanwhile, an increasing number of therapeutic agents (e.g. small molecule drugs, nucleic acids and antibodies) to selectively target CSCs have been screened or proposed in recent years. Drug delivery technology-based approaches hold great potential for tackling the limitations impeding clinical applications of CSC-specific agents, such as poor water solubility, short circulation time and inconsistent stability. Properly designed nanocarrier-based therapeutic agents (or nanomedicines) offer new possibilities of penetrating CSC niches and significantly increasing therapeutic drug accumulation in CSCs, which are difficult for free drug counterparts. In addition, intelligent nanomedicine holds great promise to overcome pump-mediated multidrug resistance which is driven by ATP and to decrease detrimental effects on normal somatic stem cells. In this review, we summarise the distinctive biological processes related to CSCs to highlight strategies against inherently drug-resistant CSCs. We then focus on some representative examples that give a glimpse into state-of-the-art nanomedicine approaches developed for CSCs elimination. A perspective on innovative therapeutic strategies and the potential direction of nanomedicine-based CSC therapy in the near future is also presented.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cancer Cells and Metastasis · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The clonal evolution of tumor cell populations10.1126/science.959840 ↗
2. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized10.1016/j.ccr.2010.10.012 ↗
3. Tumour heterogeneity and cancer cell plasticity10.1038/nature12624 ↗
4. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell10.1038/nm0797-730 ↗
5. Stem cells, cancer, and cancer stem cells10.1038/35102167 ↗
6. Prospective identification of tumorigenic breast cancer cells10.1073/pnas.0530291100 ↗
7. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content10.1016/j.cell.2009.12.007 ↗
8. Identification of human brain tumour initiating cells10.1038/nature03128 ↗
9. Identification and expansion of the tumorigenic lung cancer stem cell population10.1038/sj.cdd.4402283 ↗
10. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice10.1038/nature05372 ↗
11. Identification and expansion of human colon-cancer-initiating cells10.1038/nature05384 ↗
12. Cancer stem cells and radiotherapy: new insights into tumor radioresistance10.1093/jnci/djj505 ↗
13. Significance of CD90+ cancer stem cells in human liver cancer10.1016/j.ccr.2008.01.013 ↗
14. Identification of pancreatic cancer stem cells10.1158/0008-5472.CAN-06-2030 ↗
15. Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? an analysis10.1093/carcin/bgp259 ↗
16. Defining the mode of tumour growth by clonal analysis10.1038/nature11344 ↗
17. A restricted cell population propagates glioblastoma growth after chemotherapy10.1038/nature11287 ↗
18. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas10.1126/science.1224676 ↗
19. Chemotherapy resistance of glioblastoma stem cells10.1038/sj.cdd.4401872 ↗
20. let-7 regulates self renewal and tumorigenicity of breast cancer cells10.1016/j.cell.2007.10.054 ↗
21. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy10.1371/journal.pone.0002428 ↗
22. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling10.1158/0008-5472.CAN-12-1733 ↗
23. Association of reactive oxygen species levels and radioresistance in cancer stem cells10.1038/nature07733 ↗
24. Tumour stem cells and drug resistance10.1038/nrc1590 ↗
25. Cancer stem cells and drug resistance: the potential of nanomedicine10.2217/nnm.12.22 ↗
26. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway10.1038/sj.onc.1210811 ↗
27. The role of cancer stem cells in relapse of solid tumors10.2741/e478 ↗
28. Suppression of cancer relapse and metastasis by inhibiting cancer stemness10.1073/pnas.1424171112 ↗
29. Cancer stem cells: targeting the root of cancer relapse10.1038/nrd4560 ↗
30. Unravelling cancer stem cell potential10.1038/nrc3597 ↗
31. Understanding and targeting cancer stem cells: therapeutic implications and challenges10.1038/aps.2013.27 ↗
32. Identification of selective inhibitors of cancer stem cells by high-throughput screening10.1016/j.cell.2009.06.034 ↗
33. Targeting cancer stem cells by curcumin and clinical applications10.1016/j.canlet.2014.01.012 ↗
34. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells10.1016/j.cell.2012.03.049 ↗
35. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells10.1158/1078-0432.CCR-09-2937 ↗
36. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD4410.1038/nm.2284 ↗
37. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 110.1016/j.stem.2010.11.010 ↗
38. Small-molecule delivery by nanoparticles for anticancer therapy10.1016/j.molmed.2010.08.001 ↗
39. Nanoparticle therapeutics: an emerging treatment modality for cancer10.1038/nrd2614 ↗
40. Update on current and potential nanoparticle cancer therapies10.1097/CCO.0000000000000012 ↗
41. Engineered nanoparticles for drug delivery in cancer therapy10.1002/anie.201403036 ↗
42. Doxil(R)–the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
43. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan10.1200/JCO.2001.19.14.3312 ↗
44. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer10.1016/j.ygyno.2004.07.011 ↗
45. Can nanomedicines kill cancer stem cells?10.1016/j.addr.2013.09.016 ↗
46. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors10.4161/cbt.11.5.14410 ↗
47. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells10.1016/j.biomaterials.2014.10.018 ↗
48. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
49. Cancer stem cells: an evolving concept10.1038/nrc3184 ↗
50. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?10.1016/j.stem.2015.02.015 ↗
51. Cancer stem cells: the challenges ahead10.1038/ncb2717 ↗
52. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers10.1089/scd.2008.0302 ↗
53. Opinion: the origin of the cancer stem cell: current controversies and new insights10.1038/nrc1740 ↗
54. The origin of cancer stem cells
55. The epithelial-mesenchymal transition generates cells with properties of stem cells10.1016/j.cell.2008.03.027 ↗
56. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response10.1038/nature05236 ↗
57. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells10.1073/pnas.0606599104 ↗
58. Multidrug resistance in cancer: role of ATP-dependent transporters10.1038/nrc706 ↗
59. Breast cancer, side population cells and ABCG2 expression10.1016/j.canlet.2012.03.041 ↗
60. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo10.1084/jem.183.4.1797 ↗
61. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells10.1158/0008-5472.CAN-06-3557 ↗
62. A distinct “side population” of cells with high drug efflux capacity in human tumor cells10.1073/pnas.0400067101 ↗
63. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein
64. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A10.1002/ijc.11444 ↗
65. Pharmacological strategies for overcoming multidrug resistance10.2174/138945006777709593 ↗
66. Overexpression of CD133 promotes drug resistance in C6 glioma cells10.1158/1541-7786.MCR-09-0383 ↗
67. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter10.1074/jbc.M308700200 ↗
68. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma10.1158/0008-5472.CAN-04-3327 ↗
69. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein10.1177/107327480301000207 ↗
70. Targeting Wnt signaling: can we safely eradicate cancer stem cells?10.1158/1078-0432.CCR-09-2943 ↗
71. Targeting Hedgehog–a cancer stem cell pathway10.1158/1078-0432.CCR-09-2846 ↗
72. Targeting Notch to target cancer stem cells10.1158/1078-0432.CCR-09-2823 ↗
73. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways10.1038/nrclinonc.2010.196 ↗
74. Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects10.1097/MOH.0b013e328303b9df ↗
75. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer10.1158/1541-7786.MCR-10-0457 ↗
76. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations10.1038/sj.onc.1208511 ↗
77. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer10.1136/gut.2007.148189 ↗
78. Hedgehog signalling in prostate regeneration, neoplasia and metastasis10.1038/nature02962 ↗
79. The role of apoptosis in cancer development and treatment response10.1038/nrc1560 ↗
80. The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential10.1084/jem.191.2.253 ↗
81. A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition10.1016/j.stem.2012.12.011 ↗
82. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment10.1016/j.ccr.2011.07.017 ↗
83. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls10.1038/nrd2781 ↗
84. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the Notch pathway10.1074/jbc.M113.477950 ↗
85. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFkappaB signaling
86. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-410.1016/j.stem.2007.08.001 ↗
87. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts10.1172/JCI39397 ↗
88. Metastatic stem cells: sources, niches, and vital pathways10.1016/j.stem.2014.02.002 ↗
89. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment10.1007/s13277-013-1561-x ↗
90. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours10.1038/nature10525 ↗
91. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor10.1158/0008-5472.CAN-06-1010 ↗
92. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment10.1038/ncb2048 ↗
93. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells10.1016/j.ccr.2009.03.018 ↗
94. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia10.1038/nature08851 ↗
95. Targeting of CD44 eradicates human acute myeloid leukemic stem cells10.1038/nm1483 ↗
96. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells10.1016/j.stem.2009.04.018 ↗
97. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells10.1016/j.stem.2010.11.014 ↗
98. CD13 is a therapeutic target in human liver cancer stem cells10.1172/JCI42550 ↗
99. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment10.1073/pnas.0905653106 ↗
100. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice10.1634/stemcells.2008-0332 ↗